Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The phase 3 ADVANCE-SURMOUNT-KIDS study, officially titled “Effic...

Lilly Targets Pediatric Obesity With New Tirzepatide Trial: What Investors Should Watch

There’s a lot to be optimistic about in the Consumer Cyclical sector as 2 analysts just weighed in on Holley (HLLY) and Avery Dennison (AVY) with b...

Analysts Offer Insights on Consumer Cyclical Companies: Holley (HLLY) and Avery Dennison (AVY)

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company is running a new observational study in the...

Lilly’s AI Retinal Scan Study Adds a New Angle to Alzheimer’s Investing

The stock of Eli Lilly ($LLY) is up 4% after the U.S. Food and Drug Administration (FDA) approved “Onswik,” a once-weekly insulin that treats adult...

Eli Lilly Stock (LLY) Jumps 4% After FDA Approves Diabetes Insulin

RBC Capital analyst Trung Huynh maintained a Buy rating on Eli Lilly & Co on September 21 and set a price target of $1,500.00. The company’s shares...

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Citi analyst Laura Sutcliffe maintained a Hold rating on CSL today and set a price target of A$160.00. Sutcliffe covers the Healthcare sector, focu...

Citi Sticks to Its Hold Rating for CSL (CMXHF)

Holley ( ($HLLY) ) has shared an announcement. On September 22, 2026, Holley Performance Brands voluntarily prepaid $10 million of outstanding prin...

Holley Accelerates Debt Reduction with Term Loan Prepayment

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The study titled “A Phase 1…Study to Investigate Safety, Tolerabi...

Eli Lilly’s New Obesity Candidate LY4329090: Early Trial Update and Investor Watchpoints

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The study, officially titled A Study to Investigate the Safety, T...

Eli Lilly Completes Key Phase 1 Study of Remternetug in China: What Investors Should Watch Next

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pyxis Oncology (PYXS), Moderna (MRNA) and Eli Lill...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (PYXS), Moderna (MRNA) and Eli Lilly & Co (LLY)

Shares in pharmaceuticals group Roche ($RHHBY) put on around 2% in pre-market trading today after it said that its new expiremental obesity drug co...

Roche Stock (RHHBY) Rises as New Obesity Drug Promises to Slash Weight By a Fifth


Novo shares fell 7.96% to $39.80 on Monday after its growth strategy, disclosed at its Capital Markets Day in London, failed to impress investors
...

Novo Stock (NVO): Deutsche Bank Keeps Sell Rating, Says Growth Strategy ‘Underwhelming on Multiple Fronts’

Nelly Group AB ( ($SE:NELLY) ) just unveiled an update. Nelly Group AB has repurchased 140,000 of its own ordinary shares on Nasdaq Stockholm betwe...

Nelly Group Steps Up Share Buybacks to Optimise Capital Structure

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The study A Single-ascending and Multiple-ascending Dose Study of...

Eli Lilly’s LY3971297 Trial Completion Signals Next Steps in Cardio-Metabolic Pipeline

Shares in Danish obesity drugmaker Novo ($NVO) fell by 7% to around $40 on Monday morning, despite the company’s success in its late-stage Reimagin...

Novo Stock (NVO) Sinks Despite Beating Eli Lilly in New CagriSema Obesity Trial

Shares of Danish drug giant Novo ($NVO) dropped more than 5% to around $41 in Monday’s pre-market session. The decline came after CEO Mike Doustdar...

Why Is Novo Stock (NVO) Falling in Pre-Market Today, September 21?

Analysts are intrested in these 5 stocks: ( ($ECHO) ), ( ($ENB) ), ( ($RIVN) ), ( ($IOT) ) and ( ($LLY) ). Here is a breakdown of their recent


Echostar, Enbridge, Rivian, Samsara, Eli Lilly Trending

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company is launching a Phase 2 study called FORAY t...

Lilly’s New FORAY: Vepugratinib Targets FGFR3-Driven Bladder Cancer

The pharma giant is the dominant player in the obesity drug space. 


Eli Lilly Stock (LLY) Gets New Buy Rating as Weight-Loss Drug Sales Accelerate

Analysts have been eager to weigh in on the Consumer Cyclical sector with new ratings on Holley (HLLY), Yeti Holdings (YETI) and Nike (NKE). Holley...

Analysts Offer Insights on Consumer Cyclical Companies: Holley (HLLY), Yeti Holdings (YETI) and Nike (NKE)

RBC Capital analyst Trung Huynh maintained a Buy rating on Eli Lilly & Co yesterday and set a price target of $1,500.00. According to TipRanks, Huy...

The company has a 60% share of the weight-loss drug market. 


Eli Lilly Stock (LLY) Has 45% Upside, Says Citigroup

Nelly Group AB ( ($SE:NELLY) ) has issued an update. Nelly Group AB has continued its share buyback programme, repurchasing 143,000 ordinary shares...

Nelly Group Expands Share Buyback to Boost Capital Structure

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The study, officially titled “A Phase 1, Open-Label, Randomized, ...

Lilly Refines Abemaciclib Delivery in New Phase 1 Study, Supporting Long-Term Oncology Strategy

The Schwab U.S. Dividend Equity ETF (SCHD) and the Vanguard Dividend Appreciation ETF (VIG) are two popular dividend ETFs, but they are built for d...

SCHD vs. VIG: Which Dividend ETF Has the Edge in 2026?

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The study, officially titled “Tirzepatide Study of Renal Function...

Lilly’s Tirzepatide Targets Kidney Risk: What This Completed Trial Means for LLY Investors

U.S. pharmaceutical giant Eli Lilly ($LLY) has announced that it completed its acquisition of AtaiBeckley (ATAI), a biopharmaceutical company devel...

Eli Lilly Stock (LLY) in Focus as Company Completes $3.8 Billion AtaiBeckley Purchase

Novo Nordisk shares ($NVO) fell by 2% to about $43 early Friday after Morgan Stanley analyst Thibault Boutherin downgraded the Danish pharma giant ...

Novo Nordisk Stock (NVO) Falls After Morgan Stanley’s Sell Call on Market Share Loss to Eli Lilly, Patent Cliff

Citi analyst Laura Sutcliffe maintained a Hold rating on CSL today and set a price target of A$160.00. According to TipRanks, Sutcliffe is a 3-star...

Citi Sticks to Their Hold Rating for CSL (CMXHF)

Cardiovascular disease treatments are potentially lucrative for the pharma industry. 


Eli Lilly Stock (LLY) Falls on Competitor Novartis’ Cholesterol Drug Setback

RedHill Biopharma ($RHDL) has said the acquisition from Ferring of commercialization rights to two established gastrointestinal (GI) FDA-approved d...

RedHill Biopharma Pushes for Growth Securing Rights to Ferring’s $37M Gastrointestinal Drugs Portfolio

Nelly Group AB ( ($SE:NELLY) ) has provided an announcement. Nelly Group AB has continued its share repurchase program, buying back a total of 148,...

Nelly Group Boosts Treasury Position With New Share Buybacks

Novo Nordisk’s ($NVO) shares in Copenhagen edged lower on Monday afternoon. This came even after the Danish pharma giant said in a statement that i...

Novo Nordisk Stock (NVO) Falls Despite Success in Children’s Weight-Loss Trial

JPMorgan Chase ($JPM) is pounding the table on the stock of pharmaceutical giant Eli Lilly ($LLY) as sales of its weight-loss drugs accelerate. Chr...

Eli Lilly Stock (LLY) Gets a Bullish Note from JPMorgan Chase

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Phase 1 Inflammation Study in Focus as Eli Lilly Advances New Ora...

Eli Lilly’s New Phase 1 Inflammation Drug LY5625575 Enters the Spotlight

Wall Street investment bank Raymond James Financial ($RJF) has named Ally Financial ($ALLY) to top bank stock to own now.


Ally Financial Stock (ALLY) Is Tops Among Banks, Says Raymond James

There’s a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on S&P Global (SPGI) and Ally Financial (ALLY) with bull...

Analysts Offer Insights on Financial Companies: S&P Global (SPGI) and Ally Financial (ALLY)

UBS analyst David Low maintained a Buy rating on CSL today and set a price target of A$181.00. Low covers the Healthcare sector, focusing on stocks...

UBS Sticks to Its Buy Rating for CSL (CMXHF)

RedHill Biopharma ($RDHL) divested its Talicia business to Apotex Health Corp. in an $18 million upfront plus potential milestones deal as part of ...

RedHill Sells its Talicia® H. pylori Drug Business to Apotex in $18M Deal to Fuel Growth

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Disc Medicine (IRON), Eli Lilly & Co (LLY) and Rocke...

Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Eli Lilly & Co (LLY) and Rocket Pharmaceuticals (RCKT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immunic (IMUX), Incyte (INCY) and Eli Lilly & Co (LL...

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Incyte (INCY) and Eli Lilly & Co (LLY)

Nelly Group AB ( ($SE:NELLY) ) has shared an update. Nelly Group AB has continued its share buyback programme, repurchasing 150,000 ordinary shares...

Barclays analyst Emily Field maintained a Buy rating on Eli Lilly & Co today and set a price target of $1,400.00. According to TipRanks, Field is a...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LLY	$1,183.46	+0.13%	1.92M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LLY	$1,183.46	+0.1%	1.92M
3
4
5
6

LLY

Get Eli Lilly and Company Data in Excel

Get Eli Lilly and Company Data in Excel